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Abstract: Botulinum toxin A inhibits neuromuscular transmission. It has become a drug 
with many indications. The range of clinical applications has grown to encompass several 
neurological and non-neurological conditions. One of the most recent achievements in the 
field is the observation that botulinum toxin A provides benefit in diseases of the 
gastrointestinal tract. Although toxin blocks cholinergic nerve endings in the autonomic 
nervous system, it has also been shown that it does not block non-adrenergic  
non-cholinergic responses mediated by nitric oxide. This has promoted further interest in 
using botulinum toxin A as a treatment for overactive smooth muscles and sphincters.  
The introduction of this therapy has made the treatment of several clinical conditions easier, 
in the outpatient setting, at a lower cost and without permanent complications. This review 
presents current data on the use of botulinum toxin A in the treatment of pathological 
conditions of the gastrointestinal tract. 
Keywords: anus; physiopathology; autonomic nervous system diseases; biliary diseases; 
botulinum toxin; therapeutic use; chronic constipation; enteric nervous system; esophageal 
achalasia; esophageal diseases; exocytosis; fissure-in-ano; gastric emptying; gastrointestinal 
motility; membrane fusion; membrane proteins; neuromuscular agents; obesity; pain; spasm 
 
OPEN ACCESS 
Toxins 2015, 7 1883 
 
 
1. Introduction 
Although the therapeutic potential of botulinum toxin (BT) for skeletal muscle disorders was first 
realized in the 1970s [1], it was not until nearly two decades later that it was also shown to be effective 
in the gastrointestinal tract (GIT) [2–5]. Since then, however, there has been a rapid increase in the 
number of reports in a variety of GIT conditions characterized by dysfunctional smooth muscle [5,6]. 
This article will review the BT efficacy in the treatment of these conditions. In particular, we have taken 
into account all applications at all level of the GIT. We have reported the latest findings of the literature 
on the BT use in the treatment of GIT diseases. We believe that the introduction of BT injection in the 
treatment of these patients represents an innovation equal to the introduction of laparoscopy. The 
introduction of this therapy has made the treatment of several clinical conditions easier, in the outpatient 
setting, at a lower cost and without permanent complications. 
2. Background 
Normal GIT motility depends on intrinsic neurons contained in the enteric nervous system (ENS), 
with significant modulatory input being provided by the central nervous system (CNS) via autonomic 
sympathetic and parasympathetic nerves [7,8]. Immediate control of muscle tone in the gut reflects a 
balance between both excitatory (predominantly cholinergic) and inhibitory (predominantly nitrinergic). 
In some disease states, this balance is disrupted, usually due to a relatively selective loss of inhibitory 
neurons [9–11]. In this setting, BT, by blocking excitatory neurotransmitter release, can restore the 
balance and cause a decrease in the resting tone of the muscle involved. 
Although BT can clearly inhibit the release of acetylcholine, little else is known about its effects in 
GIT muscle. Thus, while nitric oxide (NO) release is not affected—which is to be expected, since this is 
not a vesicular process—the specific effects on other potentially important neurotransmitters has not 
been well documented [12,13]. Further, there is some suggestion that it may also inhibit the 
responsiveness of smooth muscle to exogenous stimuli, an effect that is quite unique to the GIT. 
GIT smooth muscle has an inherent motility and coordinated, aimed at the progression of ingested 
food from the oropharynx to the anal canal. The different regions of the gastrointestinal tract motility 
own and have a characteristic, capable, however, each play a specific role. The term includes motility, 
in fact, a number of events summarized as follows: 
1. Ability of smooth muscle cells to contract (myogenic event); 
2. Coordination of the contraction of smooth muscles, nerves through intrinsic and extrinsic 
(neurogenic event); 
3. Coordinated muscle contraction, with subsequent increase of the intraluminal pressure; 
4. Propulsion of content, which is the final event with the participation of the above. 
All these functions are under the direct control of the so-called ENS. It consists of all the neurons of 
the gastrointestinal tract and shows an independent function of the central nervous system, so as to merit 
the label “brain of the gut”. 
A deficiency of enteric neurons causes obstruction and lack of intestinal propulsion [14]. The ENS is 
composed of two main ganglionated plexuses (Auerbach’s myenteric plexus and Meissner’s  
sub-mucous plexus) and non-ganglionated plexuses (the longitudinal muscle plexus, the circular muscle 
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plexus, the plexus of the muscularis mucosae, and the mucosal plexus) [8]. Intraparietal neurons 
encompass motor excitatory and inhibitory neurons, interneurons and intrinsic sensory neurons. 
Sympathetic and parasympathetic neurons also innervate the GIT. The primary excitatory transmitter is 
ACh, while inhibitory transmitters are NO, adenosine triphosphate (ATP), and VIP [8]. 
At the cellular level, smooth muscle contraction and relaxation are regulated by changes in cytosol 
calcium levels [15]. These functions depend on the intrinsic electrical and mechanical properties  
of GIT smooth muscles and are regulated by the ENS and by sympathetic and parasympathetic  
influences [8]. Hormones also influence GIT motility [16]. Interstitial cells of Cajal act as local 
pacemakers to generate the rhythmic activity of the circular muscle layer throughout the GIT. Motor 
neurons control the musculature indirectly, through their action on Cajal’s cells. Substances, such as 
histamine, serotonin, adenosine, and eicosanoids, produced by non-neural cells, can influence smooth 
muscle activity [17]. 
3. Esophageal Applications 
3.1. Cricopharyngeal Dysphagia 
Dysphagia associated with cricopharingeal (CP) muscle dysfunction has a significant impact on 
overall patient quality of life [18]. CP dysphagia, either idiopathic or secondary to various neurologic or 
muscular conditions, is characterized by incomplete or poorly coordinated opening of the upper 
esophageal sphincter (UES) during swallowing. This proximal dysphagia can result in laryngeal 
penetration or tracheal aspiration of swallowed food. The CP muscle is therefore often a target of surgical 
interventions for dysphagia, including bougie or balloon dilatation, myotomy and chemodenervation by 
treatment with BT [18–23]. UES dilation is often effective and of low risk, but also has a short clinical 
effect. Transcervical CP myotomy is effective in treating CP dysphagia, but has significant risk of 
infection, salivary fistula formation, and recurrent laryngeal nerve injury [24]. Endoscopic laser CP 
myotomy was described in the early 1990s, with evidence of successful treatment in multiple patient 
series. CP myotomy improves UES opening, but will not alter pharyngeal muscle contractile forces, and 
therefore may not benefit every patient with CP dysphagia. Traditionally, CP myotomy has been the 
mainstay of treatment but other options such as dilation and BT injection have been used with good 
results [18,23]. BT injection into the CP muscle to treat dysphagia was first described in 1994 by 
Schneider and co-workers, [25] in a series of 7 patients, as an alternative treatment to the more invasive 
myotomy procedures. 
A number of injection techniques have been employed including rigid endoscopy with 
electromyographic control, flexible endoscopy, and an open technique with various doses (10–50 units). 
Endoscopically, 3 to 4 injections of BT can be delivered to the dorsomedial and bilateral ventromedial 
compartments of CP muscle. Furthermore, the location of the CP muscle has been verified by EMG in 
a number of studies especially in the otolaryngology literature. 
CP injection of BT has distinct appeal in patients who are not ideal candidates for longer general 
anesthesia or in whom the temporary nature of BT injection is warranted. It may be advantageous to 
pursue CP injection of BT in patients in whom multilevel dysphagia is suspected and in whom the 
clinician suspects that there may be some detriment to treatment directed at the UES. Additionally,  
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CP injection of BT is a diagnostic tools used by clinicians to identify patients who may potentially benefit 
from CP myotomy [18,20,21,26]. A review of the literature identified 20 studies that focused on the use 
of CP injection of BT (Table 1). 
Table 1. Review of the literature on the treatment of crycopharingeal dysphagia with BT injection. 
Authors Pts 
Botox 
(Unit) 
Dysport 
(Unit) 
Improvement 
Method of 
Delivery 
Causes Complications 
Schneider  
et al., 1994 
[25] 
7 
80–
120 
 5/7 (71%) GA, EGD 
Stroke, CN palsies, 
supraglottic or oropharyngeal 
cancer, reflux disease 
None 
Atkinson and 
Rees, 1997 
[27] 
5 5–20  4/5 (80%) 
CT guided 
injection 
Stroke, CN palsies, bulbar 
palsy 
Left vocal fold 
paresis, 
aspiration 
pneumonia  
Blitzer and 
Brin, 1997 
[26] 
6 10  6/6 (100%) 
Percutaneous 
injection 
CVA, partial 
pharyngectomy, small 
Zenker’s diverticulum 
None 
Alberty et al., 
2000 [28] 
10 30  10/10 (100%)  GA, EGD CVA, idiopathic polymiositis None 
Shaw and 
Searl, 2001 
[29] 
12 25–50  10/12 (83%) 
GA, EGD, 
open technique 
Progressive neuropathy, 
oculopharyngeal dysphagia, 
skull base tumor resection, 
total laryngectomy, CVA, 
partial pharyngectomy, CNS 
neuropathy 
Pharyngeal tear, 
worsening 
dysphagia 
Haapaniemi  
et al., 2001 
[30] 
4 14–50  3/4 (75%) GA, EGD 
Brain stem stroke, inclusion 
body myositis,peripheral 
motor neuropathy, CVA 
None 
Moerman  
et al., 2002 
[31] 
4 100  4/4 (100%) GA 
Head and neck cancer 
resection including total 
laryngectomy, radiation 
None 
Parameswaran  
and Soliman,  
2002 [32] 
12 10–30  11/12 (92%) 
EGD with 
mask 
ventilation and 
apneic 
technique 
Idiopathic, radiation, CVA, 
total laryngectomy, ALS, 
Parkinson’s disease 
Neck cellulitis 
(concurrent 
thyroglossal 
duct excision) 
Zaninotto  
et al., 2004 
[33] 
21 4–10  9/21 (43%) 
Percutaneous 
with EMG 
CNS disease, peripheral 
neuropathies, idiopathic 
Death of 
aspiration 
(attributed to 
underlying 
disease) 
Murry et al.,  
2005 [34] 
13 100  
11/13 (85%) 
2/13 
improvement 
after second 
injection 
EMG-guided 
transcutaneous 
approach 
Stroke, head and neck 
surgery, cranial neuropathies, 
MVC, chemical inhalation, 
radiation therapy or 
lymphoma 
None 
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Table 1. Cont. 
Authors Pts 
Botox 
(Unit) 
Dysport 
(Unit) 
Improvement 
Method of 
Delivery 
Causes Complications 
Kim et al.,  
2006 [35] 
8 100  5/8 (62.5%) 
Flexible 
endoscopy 
CVA None 
Restivo et al., 
2006 [36] 
12  60 12/12 (100%) 
EMG-guided 
transcutaneous 
approach 
Diabetic neuropathy None 
Alfonsi et al., 
2010 [37] 
34 15  17/34 (50%) 
EMG-guided 
transcutaneous 
approach 
MS, Multiple system 
atrophy, Parkinson’s 
disease, progressive 
sopranuclear palsy,  
ataxia-teleangectasia 
None 
Restivo et al., 
2011 [38] 
14 20  14/14 (100%) 
Percutaneous 
injection with 
EMG guidance 
MS None 
ALS, amyotrophic lateral scrlerosis; CN, cranial nerve; CNS, central nervous system; CT, computed tomography; CVA, cerebrovascular 
accident or stroke; EGD, esophagogastroduodenoscopy; EMG, electomyography; GA, general anesthesia; MVC, motor vehicle collision; 
SAH, subarachnoid hemorrhage; MS, multiple sclerosis. 
Only two series were of more than 20 patients; the largest study included 34 patients. The causes of 
CP dysfunction in these published series encompassed several diagnosis, including neurological 
diseases, diabetic neuropathy, external-beam radiation treatment, cerebrovascular accident, and others. 
The dosage and administration techniques of BT were also quite variable [18]. There were also different 
types of BT administered: Dysport (Ipsen, Paris, France) and Botox (Allergan, Irvine, USA); the Dysport 
doses delivered to CP muscle ranged from 60 to 180 units, and the Botox doses ranged from 4 to 120 
units [18,39]. 
In general, the majority of patients reported improved swallowing function: approximately 75% in 
combined analysis. Complications were infrequent and included transient vocal fold paresis, temporary 
worsening of dysphagia, neck cellulitis, and aspiration pneumonia. There were no reported deaths in the 
literature that were directly related to CP injection of BT. Recently, Kelly and coworkers demonstrated 
that CP injection of BT is a well-tolerated treatment for dysphagia related to CP dysfunction, with good 
efficacy in the majority of their 49 patients [18]. On the basis of these results, CP injection of BT appears 
to be effective in patients with UES dysfunction. Response to BT injection may select out a group of 
patients with higher likelihood of a more durable response to surgical myotomy [40]. Further work, 
however, is needed to define the population of patients who might have a poor response to BT treatment. 
Furthermore, non-response may indicate another etiology of dysphagia, i.e., stricture. 
Crycopharingeal Achalasia (CPA) in Children 
The condition is characterized by an incomplete relaxation or by a lack of coordination of the  
UES [22,41]. CPA is a different entity then the CP dysphagia that was see in adults. The exact cause of 
CPA is unknown. Immaturity of the interstitial cells of Cajal may explain why there have been reports 
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of spontaneous resolution of CPA seen in infants [42]. CPA has also associated with gastro-esophageal 
reflux disease and CNS abnormalities [21,22,41–44]. 
Recently, six children were identified with CPA [22]. The decision to proceed with BT therapy was 
based on ongoing severe symptoms, the necessity of altered feeds, and parent preference over a surgical 
myotomy. The number of injections ranged from 1 to 3 per patients. The mean dose was  
5.6 units/kg, with a range of 1.6 units/kg to 7.9 units/kg and a median of 6.0 units/kg. In those patients 
with multiple injections, the mean time between injections was approximately 13 months. The mean 
time to return to normal radiographic swallow study was 8.2 weeks. Two of the children benefited from 
BT injections and went on to have CP myotomy, while four of the children did not require myotomy and 
their symptoms resolved after one or two injections. The authors concluded that BT injection of CP 
muscle is a useful tool to help diagnose and treat CPA [22]. It is a feasible alternative to more invasive 
surgical procedures. However, more research is needed to elucidate the optimal dosing, frequency of 
injections, and when to move on to surgical intervention. 
3.2. Achalasia 
The major pathophysiological lesion in achalasia, which means failure to relax, results from a 
relatively specific loss of nitrergic inhibitory neurons of the LES, resulting in an inability of the sphincter 
to relax after swallowing [45]. This results in a functional obstruction and dysphagia. Although no cure 
exists for achalasia, there are a number of palliative treatments available including surgical myotomy, 
pneumatic dilation (PD), and BT injections into the LES [46–51]. Surgical myotomy has proven durable, 
but is associated with increased morbidity and mortality in high-risk surgical patients. Pneumatic dilation 
of the sphincter results in an initial symptomatic improvement in 60%–90% of patients but repeated 
dilations are often necessary. Furthermore, the procedure carries a small but significant risk of 
esophageal perforation [52–54]. Thus, BT provides a potentially attractive alternative to the above 
treatment methods [49]. 
Endoscopic injection of 25 units of BT in 4 LES quadrants is generally the standard of care. The efficacy 
of BT in achalasia has been proven by the results of several randomized trials comparing it  
to either placebo or pneumatic dilation. Table 2 summarizes the response rates to BT in patients  
with achalasia. 
In general, 75%–100% of patients show an initial response but more sustained improvement (beyond 
6 months) is seen in about two-thirds. For unclear reasons, it appears that patients older than 50 years of 
age respond at a higher rate (82% vs. 43% in younger patients). Similarly, patients with so-called 
vigorous achalasia (with the esophagus retaining some contractile ability) respond at a higher rate  
(100% vs. 52% with classic achalasia). 
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Table 2. Review of experiences using BT for the treatment of esophageal achalasia. 
Authors Description Patients Results/Conclusions 
Pasricha et al., 
1995 [5] 
BT vs. Placebo 21 67% improvement at 6 weeks 
Annese et al., 
1996 [55] 
BT vs. placebo  
vs. PBD 
16 100% improvement at 1 month. BT is as effective as pneumatic dilatation 
Fiorini et al.,  
1996 [56] 
BT vs. Placebo 13 72% improvement at 3 month 
Pasricha et al., 
1996 [57] 
BT 31 60% (82% of those aged > 50) improvement at 3 month 
Fishman et al., 
1996 [58] 
BT 65 
60 idiopatic cases: BT treatment improved symptoms of dysphagia, Chet 
pain and regurgitation in the majority of patients. 5 secondary cases: There 
was no response to BT in 4 patients. Patients, who respond to a first BT 
injection but relapse, may respond to a second treatment 
Cuilliere et al., 
1997 [59] 
BT 55 60% improvement at 6 month 
Kolbasnik et al., 
1999 [60] 
BT 30 
Symptomatic improvement for >3 month was seen in 77% of patient.  
7 patient had a sustained response after a single injection; 16 relapsed and 
required re-treatment  
Annese et al., 
1999 [61] 
Botox vs. 
Dysport 
78 
Comparable efficacy in esophageal achalasia after up to 6 month after 
treatment 
Muehldorfer et al., 
1999 [62] 
BT vs. PBD 24 
The two treatment had equal initial success rate (dilatation 83%, BT 75%). 
In the long term the efficacy of BT injection was statistically significantly 
and shorter than that of balloon dilatation 
Greaves et al., 
1999 [63] 
BT 11 
The relapse rate was 73% within 2 years from treatment. There were a 
beneficial effect on dysphagia, no improvement in chest pain or regurgitation 
scores, and no reduction of mean LES pressure were improved at 6 weeks 
Wehrmann et al., 
1999 [64] 
BT in high  
risk patients 
20 
80% were improved at 6 weeks. Mean cardia diameter was increased from 
2.1 mm to 3.2 mm. The patients who initially had a symptomatic relapse 
after an average of 5 months. BT re-injections were efficacious 
Hurwitz et al., 
2000 [65] 
BT in children 23 
The mean duration of effect in 19 responders was 4.2 months. 50% of the 
patients required an additional procedure (PD, surgery) on average  
7 months after the first treatment 
Annese et al., 
2000 [66] 
BT dose raging 
study 
118 
82% of the patients were responders at 1 month. No dose related effect was 
observed. Vigorous achalasia was the main determinant of BT response 
Mikaeli et al., 
2001 [67] 
BT vs. PBD 40 
Cumulative 12-month remission rate was significantly higher after a single 
PD (53%) compared to a single BT injection (15%, p < 0.01).  
The 12-month estimated adjusted hazard for relapse and need for 
retreatment for BT group was 2.69 times that of the PD group 
Allescher et al., 
2001 [68] 
BT vs. PBD 37 
After 24 months a single PD was superior to a single BT injection,  
and after 48 months all patients treated for BT injection had experienced  
a symptomatic relapse 
Ghoshal et al., 
2001 [69] 
BT vs. PBD 17 Both therapies resulted in a significant reduction in LES pressure 
Zarate et al.,  
2002 [70] 
BT 17 
The effect of BT injection wanes with time in elderly patients, necessitating 
repeated injections to keep the patients symptoms free 
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Table 2. Cont. 
Authors Description Patients Results/Conclusions 
D’Onofrio et al., 
2002 [71] 
BT 37 
Of the 35 patients followed, 12 had a relapse and were treated; 4 out of 12 
did not respond after treatment. One or two BT injections result in a clinical 
and objective improvement in about 84% of achalasia patients and are not 
associated with serious side-effects; patients over 50 years showed better 
benefit than younger patients 
Neubrand et al., 
2002 [72] 
BT 25 
Good results after 2.5 years of median follow up in 9 of 25 patient that were 
significantly older than 14 patients for whom BT treatment was unsuccessful 
Brant et al.,  
2003 [73] 
BT in Chagas’ 
disease 
24 
Over a period of 6 month, clinical improvement of dysphagia was 
statistically significant (p < 0.001) in patients receiving BT when compared 
with the placebo. Esophageal emptying time in BT group was significantly 
lower than in the placebo (p = 0.04) after 90 days 
Bansal et al.,  
2003 [74] 
BT vs. PBD 32 
After 12 month follow up 16 of 18 patients of PBD were in clinical 
remission despite 6 of 16 of BT group 
Martinek et al., 
2003 [75] 
BT vs. PBD 41 
16 patients had BT injection from the antegrade angle only (group A),  
15 both from antegrade than retrograde (group B) and 10 had subsequent PD 
(group C). 93% had an immediate clinical response after 1 month ad 49 
were in remission after 22 months. Better responders were older and with 
lower LES pressure. Patients in group C had better results at 1 and 2 year 
Vela et al.,  
2004 [76] 
PBD vs. HM vs. 
BT 
232 
111 patients underwent PBD, 72 HM and 39 elderly patients BT injection. 
48 patients had already surgical treatment and underwent to PBD or redo-
HM. PBD and HM are the best treatments for untreated achalasia and are 
less successful after surgery. BT group needed repeated injections and their 
symptoms improving lasted for a mean period of 6.2 months 
PBD vs. HM in 
patient with  
prior surgery 
Zaninotto et al., 
2004 [77] 
BT vs. HM 80 
After 6 months similar results were reported in the 2 groups of 40 patients, 
but after 2 years 87.5% of patients of surgical groups were symptoms free 
vs. 34% of BT group (p < 0.05) 
Mikaeli et al., 
2004 [78] 
BT + PBD vs. 
PBD 
24 
BT + PBD (case-group) had a significant higher cumulative remission rate 
compared to control (PBD) group (24.6 vs. 12.6 months P < 0.01) and a 
significant reduction in symptom-score (76% vs. 53% P < 0.001). Control 
group needed a 35 mm PBD vs. 30 mm of case group  
Dughera et al., 
2005 [79]  
BT elderly 12 
After 12 months of follow-up, up to 70% of patients were considered 
responders. They underwent 2 BT injection (time 0 and after 1 month). 
Average age 86 y.o. ASA 3 or 4 
Bassotti et al., 
2006 [80] 
BT elderly 33 
Patients underwent 2 BT injection (time 0 and after 1 month). 78% were 
considered responders after 1 year and 54% after 2 years. No relationship 
was found between baseline LES pressure and symptoms score 
Mikaeli et al., 
2006 [81] 
BT + PBD vs. 
PBD 
54 
77% of patients of BT + PBD group were in remission after 1 year vs. 62% 
of PBD group and showed a significant reduction in barium volume at the 
various times intervals post-treatment 
Zhu et al.,  
2009 [82] 
BT vs. PBD vs.  
BT + PBD 
90 
LES pressure and symptom score in group C (BT + PBD) were significantly 
lower compared with those in group A (BT) or group B (PBD) (p < 0.05). 
At 2 years after treatment, the response rate in group C remained 56.67% vs. 
35.71% (group B) and 13.79% (group A) (p < 0.05) 
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Table 2. Cont. 
Authors Description Patients Results/Conclusions 
Kroupa et al.,  
2010 [83] 
BT + PBD vs. 
PBD 
91 
The mean duration of follow-up was 48 months (12–96 months). 41 of 51 
patients were followed up more than 2 years. Effect of therapy lasted in 75% 
(31/41) of them. The cumulative 5 years remission rate in combined treated 
patients was higher than in controls bu not statistically significant. (p = 0.07). 
Injection of BT followed by PD seems to be effective for long-term result 
but the combined therapy is not significantly superior to PD alone 
Gutschow et al., 
2010 [84] 
BT vs. PBD vs. 
PBD-HM vs. HM 
41 
Patients of BT group (n = 7) had the lower mean LES pressure (18.1 mm Hg) 
and higher recurrence rate (71.4%) compared to patients of PBD group  
(n = 16, 34.8 mm Hg—50%), PBD-HM group (n = 14, 22.2 mm Hg—35.7%) 
and HM group (n = 6, 36.4 mm Hg—16.7%) 
Bakhshipour et al., 
2010 [85] 
BT + PBD vs. 
PBD 
34 
Patient of study-group already underwent two initial PBD with a low 
response. They were randomized to receive another PBD or BT injection and 
PBD by four weeks interval. BT + PBD group had higher remission rate at 1, 
6 and 12 months compared to PBD group (87.5% vs. 67.1%, 87.5% vs. 61.1%, 
87.5% vs. 55.5%, respectively). Difference was not statistically significant 
Porter et al.,  
2011 [86] 
BT 36 
Response lasted a mean of 12.8 months and symptom relief for > 6 months was 
seen in 58.3% of patients. Chest pain, younger age and contraction amplitudes 
>180 mmHg independently predicted <6 months relief (p < 0.05 for each) 
Ciulla et al.,  
2013 [87] 
BT 68 
36 patients underwent echo-guided BT injection had complete relief of 
obstruction compared to 32 patients who underwent blind treatment. 
Cai et al.,  
2013 [88] 
BT vs. SEMS 110 
Improvements in global symptom, dysphagia scores and in LES pressure were 
significantly more marked in the SEMS group (n = 59) than in the BT group  
(n = 51). Remission rate in the SEMS group was statistically significantly 
higher than that in the BT group at 12 and 36 months [81.28 vs. 64.58  
(p < 0.05) and 49.1 vs. 4.2 (p < 0.01)]. No side effects were reported in BT 
group vs. 26 in SEMS group 
Jung et al.,  
2014 [53] 
BT vs. PBD 37 
A significant difference was observed in the mean remission duration 
between the BT injection (n = 25) and PBD (n = 12) (13 months vs. 29 
months). Independent factors predicting long-term remission included 
treatment type and the difference in the initial LES pressure  
Marjoux et al., 
2014 [48] 
BT 45 
22 patients had achalasia, 8 jackhammer esophagus, 7 distal esophageal 
spasm, 5 esophagogastric junction outflow obstruction, 1 nutcracker 
esophagus, and 2 unclassified cases. 71% were significantly improved after  
2 months and 57% remained satisfied for more than 6 months. No clear 
difference was observed in terms of response according to manometric 
diagnosis. Type 3 achalasia had the worst outcome with none of these 
patients responded to the endoscopic BT injection 
BT, Botulinum toxin; HM, Heller myotomy; LES, lower esophageal sphincter; PBD, pneumatic balloon dilatation; PD, pneumatic 
dilatation; SEMS, self-expanding metal stent. 
Several studies have compared BT to pneumatic dilation with most reporting similar initial clinical 
or manometric responses. However, the one-year remission rate after a single injection is markedly 
inferior for BT, which is to be expected given its pharmacological properties. In the only study 
comparing the two modalities in a head to head comparison, 80 patients were randomized to receive  
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100 BT units or laparoscopic surgical myotomy with fundoplication. After six months, symptom scores 
improved more in surgical patients (82% vs. 66%, p < 0.05). The drop in LES pressure was similar in 
the two groups; the reduction in esophageal diameter was greater after surgery (19% vs. 5%, p < 0.05). 
The only complication in the surgical group was one patient bled at the trocar site. The probability of 
being symptom-free at two years was 87.5% after surgery and 34% after BT (p < 0.05). The same group 
investigated the cost effectiveness of the two modalities and concluded that BT was more cost effective in 
the short term, but at two years, cost between the two groups was similar. The results of a recent  
meta-analysis suggest that PD is the more effective endoscopic treatment in the long-term (greater than 
6 months) for patients with achalasia [52]. 
BT injections into the upper GIT appear to be quite safe with very few, if any, reports of serious 
adverse effects. The incidence of gastro-esophageal reflux has not been well characterized in most 
studies but has been reported to be about 20%, by symptoms at least. There has also been some question 
in recent years whether BT prior to PD or myotomy complicates the more invasive procedures possible 
secondary to LES fibrosis. However, although previous BT injection (or PD for that matter) may make 
myotomy more challenging technically because of obliteration of tissue planes, this does not appear to 
affect the final outcome after myotomy. 
3.3. Other Esophageal Disorders 
BT has also been used in a variety of less well characterized esophageal conditions including diffuse 
esophageal spasm (DES) and patients with non-cardiac chest pain suspected to be on the basis of a 
dysfunctional esophagus. DES is a condition that is related to achalasia and may be associated with LES 
dysfunction as well [89–96]. The largest clinical trial assessing the effect of BT in DES patients 
evaluated 9 patients [97,98]. A significant reduction in symptom score was noted at week 4 and 8.  
A recent study examined 22 patients with DES or nutcracker esophagus who had primarily dysphagia 
and gave them blinded saline or BT injections in a crossover study design [94]. Results showed that 
symptoms scores and weight loss improved after BT treatment, not the saline injections, and this benefit 
was sustained for over a year in almost half of the patients. Unfortunately, there have been no other 
clinical trials evaluating BT as a treatment option for this disorder. 
In addition to dysphagia and regurgitation, chest pain can be associated with achalasia, DES, 
ineffective esophageal motility (IEM), and isolated LES dysfunction which may respond to BT 
administration as shown in previous studies. A study, with improvement of chest pain as the primary 
end-point, evaluated 29 patients with non-cardiac chest pain who received 100 BT units injection into 
the LES, same as the treatment regimen for achalasia. Seventy-two percent of the patients responded 
with at least 50% reduction in chest pain [99]. 
Similar to idiopathic achalasia, in Chagas’ disease (CD), a common disease in South  
America [73,100–104], slow esophageal emptying is due to nonrelaxation of the LES. Only one 
representative series on 24 patients has been published regarding BT in esophageal CD. The authors 
have been showed that 58% of the patients had clinical improvement of dysphagia at 6 months follow 
up. Interestingly, gender, age and LES pressure did not influence outcomes, contrary to the results 
obtained in idiopathic achalasia series [57,73]. 
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4. Gastric Applications 
4.1. Gastroparesis 
Gastroparesis or delayed gastric emptying resulting in nausea, vomiting, dyspepsia, and abdominal 
bloating is a common problem in patients seen by primary care physicians and gastroenterologists. 
Gastroparesis can occur as a result of poorly controlled diabetes mellitus, post-surgical manifestations, 
or idiopathic causes [105–108]. In recent years, BT injection into the pylorus has been investigated as a 
treatment option in this otherwise debilitating disorder. 
The initial study evaluating the BT efficacy in patients with diabetic gastroparesis assessed six 
patients with abnormal solid phase gastric emptying studies [109]. Each patient received 100 BT units 
into the pyloric sphincter and symptom scores and gastric emptying were assessed after six weeks. There 
was an improvement of subjective symptom scores of 55%, which was maintained at six weeks.  
In addition, there was a 52% improvement in gastric emptying at six weeks. Another study investigated 
the BT use in cases of idiopathic gastroparesis [110]. Ten patients were given 80–100 BT units and a 
38% reduction in symptom scores were seen at 4 weeks which correlated with findings of increased 
gastric emptying. A recent study evaluated the effects of BT on diabetic gastroparesis for  
12 weeks [105]. Eight patients received 200 BT units into the pyloric sphincter, and seven patients 
completed the 12-week follow-up. Mean symptom scores declined from 27 to 12.1 (p < 0.01). 
Furthermore, six of the seven patients gained weight (p = 0.05) and gastric emptying scan time improved 
in four patients [105]. The largest study to address this issue retrospectively evaluated 63 patients who 
met the study criteria [108]. Gastroparesis was secondary to diabetes in 26 patients (41.2%), after surgery 
in two (3.2%), and idiopathic in 35 (55.6%). Twenty-seven of 63 (43%) patients experienced a 
symptomatic response to treatment (100 to 200 units) with a mean duration of five months. Male gender 
was associated with response to therapy. However, vomiting as a major symptom was predictive of no 
response to BT [108]. Further studies were needed to address these issues and to better define potentially 
responsive patients [111–115]. 
4.2. Obesity 
BT injection into the gastric antrum may be used to transiently decrease gastric emptying as a 
treatment for obesity [116–120]. Preliminary data in rats have shown a significant loss of body weight 
associated with a reduction of dietary intake in the BT treated group. In a double blind controlled study, 
24 morbidly obese patients (mean body mass index (BMI) 43.6 ± 1.09 kg/m2) were blindly randomized 
to receive 200 BT units or placebo into the antrum and fundus of the stomach by intraparietal endoscopic 
administration [121]. The two groups were homogenous for anthropometric characteristics. Eight weeks 
after the treatment, BT patients had significantly higher weight loss (11 ± 1.09 kg vs. 5.7 ± 1.1 kg,  
p < 0.001) and BMI reduction (4 ± 0.36 kg/m2 vs. 2 ± 0.58 kg/m2, p < 0.001) than controls. No significant 
side effects or neurophysiologic changes were found. Similar results have been found in an open label 
study of 10 obese adults (BMI 31–54 kg/m2) who received 100 units (4 patients) or 300 units (6 patients) 
of BT and were followed for 16 weeks [122]. 
Further results demonstrated that BT makes weight loss easier in obese patients [123]. It seems 
conceivable that BT acts by increasing the solid gastric emptying time and reducing the solid eating 
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capacity of the stomach. However, the results in literature are controversial. In several clinical 
experiences, intragastric BT injection does not seems to reduce body weight [118,124–126]. 
4.3. Others Gastropyloric Disorders 
BT has been used to facilitate gastric emptying in patients who underwent pylorus-preserving 
duodenopancreatectomy [127]. Initial studies suggests that BT injection into the pylorus improves both 
gastric emptying and symptoms. 
Infantile hypertrophic pyloric stenosis is a congenital hereditary disorder characterized by a functional 
gastric outlet obstruction [128]. Obstruction is the result of a gradual hypertrophy of the circular smooth 
muscle of the pylorus, and the neurons that innervate the circular-muscle layer lack NO synthase. 
Recently it has been observed lack of response to BT injection in two patients with pyloric stenosis. 
Studies have shown that BT injection helps patients suffering from post-surgical pyloric clogging. BT 
injection is also used as an alternative method for the treatment of gastric emptying disorders [129–131]. 
In a recent study, the authors compared the effect of BT injection and pyloroplasty in preventing delayed 
gastric emptying after esophagectomy for esophageal cancer [115]. Sixty patients were included in the 
study: These patients were randomly divided into two groups. In group A, 30 patients underwent 
pyloroplasty, and in group B injection of 200 BT units into the pyloric sphincter muscle was used in 30 
patients. An isotope-scan three weeks after surgery showed that five patients in group A and three in 
group B had delayed gastric emptying; there was no significant difference between the two groups, and 
the success rate of BT injection was 90% [115]. BT injection may be used instead of pyloroplasty as a 
simple, effective and complication-free method to prevent gastric emptying delay. 
5. Duodenal and Biliary Applications 
5.1. Sphincter of Oddi Dysfunction (SOD) 
The sphincter of Oddi is a small ring of muscle that surrounds the biliary and pancreatic ducts just 
before they open into the duodenum. SOD is a poorly understood and controversial condition postulated 
to result in biliary pain, typically in the setting of a previous cholecystectomy. It has also been 
hypothesized that pancreatic SOD can result in pancreatic type pain and/or recurrent pancreatitis. The 
standard of SOD treatment currently is endoscopic sphincterotomy, which is a relatively high-risk 
procedure that is not uniformly effective. Hence there is interest in the use of a simpler procedure such 
as BT to serve as a therapeutic trial patients who respond to this treatment could then go on for more 
permanent relief using a sphincterotomy [132–134]. This was first suggested in a short report on two 
patients. Subsequently a larger study was reported evaluating twenty-two patients who had undergone 
cholecystectomy and had manometrically confirmed type III SOD [135]. Six weeks after 100 BT units 
injected into the sphincter, 12 patients (55%) were symptom-free, but ten patients (45%) were not. Of 
the ten patients who did not experience symptomatic benefit from BT injection, five had normal basal 
sphincter of Oddi pressures (<40 mmHg), and biliary sphincterotomy did not relieve the symptoms of 
these patients. Two of the remaining five patients with sustained sphincter hypertension after BT 
injection benefited from biliary sphincterotomy. Of the 12 patients who initially responded to BT 
injection, 11 patients remained symptom free for a median duration of six months. These patients had 
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recurrence of biliary hypertension and responded to biliary sphincterotomy. The authors concluded that 
response to BT injection may select a subset of patients who will respond to biliary sphincterotomy.  
BT has also been used with similar intent, although in an uncontrolled manner in patients with acute 
recurrent pancreatitis suspected to be due to pancreatic SOD [136]. 
The future role of BT injection in SOD still needs further investigation but current literature supports 
its use as a therapeutic trial in patients with SOD. 
5.2. Others Biliary Disorders 
BT induced relaxation of the sphincter of Oddi may help to treat patients with acalculous biliary  
pain [137]. A total of 11 patients had a positive response to BT injection of 100 UI into the sphincter of 
Oddi. Endoscopic biliary sphincterotomy has been induced a relief of biliary pain in 10 of these  
cases [137,138]. 
BT injection is as effective as endoscopic biliary stent placement in resolving cystic duct leaks in a 
canine model [139]. 
6. Pelvic and Anorectal Applications 
6.1. Pelvic Floor Dyssenergia 
Pelvic floor dyssenergia, also known as anismus, is a common cause of chronic constipation, 
hallmarked by inappropriate, paradoxical contraction or a failed relaxation of the puborectal muscle and 
EAS during defecation [2,3,140]. In normal patients, the puborectalis muscle and the EAS relax to 
straighten the anorectal angle and open the anal canal. Usually, this alteration in defecation is from 
maladaptive learning and responds to biofeedback in 60%–70% of patients as demonstrated in mostly 
single group, uncontrolled trials. Surgery has not been shown to be effective and has been largely 
discouraged as a treatment option. There are a limited number of studies evaluating the BT use in pelvic 
floor dyssenergia (Table 3). 
Table 3. Published results of treatment of pelvic floor dyssenergia with BT. 
Author Pts 
Name of Drug/Dose 
(units) 
Results Complication 
Hallan et al., 
1988 [141] 
7 Dysport—Nr 
Maximum voluntary contraction from 70 to 28 cm H2O. 
Anorectal angle from 96° to 124°. Symptomatic 
improvement in four patients.  
Incontinence in 
two patients 
Joo et al.,  
1996 [142] 
4 Botox—6–15 U 
Symptomatic improvement in all treated patients.  
Two patients relapsed.  
0 
Shafik et al., 
1998 [143] 
15 Botox—25 U 
Symptomatic improvement in 13 patients,  
on average 4, 8 months after the first treatment. 
0 
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Table 3. Cont. 
Author Pts 
Name of Drug/Dose 
(units) 
Results Complication 
Maria et al., 
2000 [144] 
4 Botox—30 U 
75% were improved at 8 weeks. Anal tone during straining 
from 96.2 mm Hg to 42.5 mm Hg at 4 weeks, and to  
63.2 mmHg at 8 weeks. Anorectal angle from 94° to 114°. 
0 
Maria et al., 
2001 [145] 
14 AR Botox—30 U 
At 2-month evaluation, a symptomatic improvement was 
found in nine patients. At defecography, the rectocele depth 
was reduced from 4.3 ± 0.6 cm to 1.8 ± 0.5 (p < 0.001) and 
the rectocele area was reduced from 9.2 ± 1.2 cm2 to  
2.8 ±1.6 cm2 (p < 0.001). The anorectal angle measured 
during straining increased from a mean of 98 ± 15° before 
treatment to a mean of 121° ± 19 ° (p = 0.001). At one-tear 
evaluation, there was no report of digitally rectal voiding 
and rectocele was no found at physical examination. 
0 
Ron et al., 2001 
[146] 
25 Botox—20 U Symptomatic improvement in 75% of the patients. 
Perianal pain in 
3 patients 
Madalinski et al., 
2002 [147] 
39 
Botox—25 U 
Nr 
Perianal pain in 
4 patients Dysport—150 U 
Albanese et al., 
2003 [148] 
10 PD Botox—100 U 
Following treatment, anal tone during straining was reduced 
from 97.4 ± 19.6 mm Hg at baseline to 40.7 ± 11.5 mm Hg 
one month after treatment (p = 0.00001); no further change 
was observed at two-month evaluation (38.2 ± 10.4 mm Hg; 
p = 0.00001 vs. baseline values). The anorectal angle during 
straining (as measured with defecography) increased from a 
mean of 90° ± 7.9° before treatment to 122.2° ± 15°  
(p = 0.0004); nine patients evacuated the barium past 
without the need for laxative or enemas. 
0 
Cadeddu et al., 
2005 [149] 
18 PD Botox—100 U 
At 2 months evaluation inspection revealed a symptomatic 
improvement in 10 patients. Anorectal manometry 
demonstrated decreased tone during straining from  
96.2 ± 17.1 mm Hg to 45.9 ± 16.2 mm Hg at 1 month 
evaluation (p < 0.00001) and to 56.1 ± 10.7 mm Hg at  
2 month (p < 0.00001). Pressure during straining was lower 
than resting anal pressure at the same times in all patients. 
Defecography after the treatment showed improvement in 
anorectal angle during straining witch increased from  
99.1° ± 8.4° to 121.7° ± 12.7° at 2 months (p < 0.00001). 
0 
Maria et al., 
2006 [150] 
24 Botox—60 U 
At 2-month evaluation inspection revealed a symptomatic 
improvement in 19 patients. Anorectal manometry 
demonstrated decreased tone during straining from  
98 ± 24 mm Hg to 56 ± 20 mmHg at 1 month evaluation  
(p < 0.01) and 56 ± 29 mm Hg at 2 months follow-up  
(p < 0.01). Defecography after the treatment showed 
improvement in anorectal angle during straining. 
0 
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Table 3. Cont. 
Author Pts 
Name of Drug/Dose 
(units) 
Results Complication 
Keshtgar et al., 
2007 [151] 
42 Botox—60 U  
BT injection (n = 21) is equally effective and less invasive 
than M of IAS (n = 21) for chronic idiopathic constipation. 
At 3 months the median preoperative SS score improved 
from 34 to 20 in BT group (p < 0.001) and from 31 to 18 in 
the M group (p < 0.002). At 12 months the score was 19 and 
14, 5 in BT and M group respectively (p < 0.0001). 
0 
Irani et al.,  
2008 [152] 
24 Botox—20 U 
Of 24 patients, 22 experienced significant improvement in 
their constipation lasting greater than 22 weeks. There was a 
statistically significant improvement from 2.1 to 6.5 bowel 
movement per week (p < 0.001). The benefit of the BTX-A 
persisted a variable period of time among the responders, 
with 12 patient (55%) demonstrating a response lasting  
6 months or more. 
5 fecal soiling 
Farid et al.,  
2009 [153] 
48 Dysport—100 U 
In BFB group (n = 24) initial improvement was recorded in 
12 patients (50%) while long-term success was recorded in 
6 patients (25%). In the BT group (n = 24) clinical 
improvement was recorded in 17 patients (70.8%) but the 
improvement persisted only in 8 patients (33.3%). There is a 
significant difference between BT group and BFB group 
regard the initial success (p = 0.008) but this significant 
difference disappeared at the end of follow-up (p = 0.23). 
Nr 
Farid et al.,  
2009 [154] 
30 Dysport—100 U 
BT injection (n = 15) achieved initial success in  
13 patients (86.7%). Long-term success persisted only in six 
patients (40%). PDPR (n = 15) achieved initial success in all 
patients (100%) with a long-term success in ten patients 
(66.6%). However this difference did not produce any 
significant value. Recurrence was observed in seven 
patients (53.8%) and five patients (33.4%) following BT 
injection and PDPR, respectively. 
0 
Keshtgar et al., 
2009 [155] 
16 Dysport—200 U 
There were significant improvements in symptoms of 
constipation, soiling, painful defecation, general health and 
behavior, and fecal impaction of rectum (p < 0.05). 
Outcome was measured by a validated SS score 
questionnaire. At 3-months follow-up, the median SS score 
improved in all children after BT injection from 32.50 to 
7.50 (p < 0.0001). At 12-months follow-up, the 
improvement of SS score in BT injection group was 
significantly more than the control group (n = 31) as 
follows: 4 vs. 15 respectively (p < 0.002). 
0 
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Table 3. Cont. 
Author Pts 
Name of Drug/Dose 
(units) 
Results Complication 
Farid et al.,  
2009 [156] 
60 Dysport—100 U  
The groups differed significantly regarding clinical 
improvement at 1 month [50% for BFB (n = 20), 75% BT 
injection (n = 20), and 95% for PDPR (n = 20), p = 0.006] 
and differences persisted at 1 year (30% for BFB, 35% BT 
injection, and 70% for PDPR, p = 0.02). BT injection seems 
to be successful for temporary treatment but PDPR is found 
to be an effective with lower morbidity in contrast to its 
higher success rate. 
Nr 
Ahmadi et al., 
2013 [157] 
88 Dysport—160 U 
Defecation of painful stool existed in 88% of patients before 
BT injection and it was reduced to 15% after BT injection 
(p = 0.0001). Stool was hard in 80% of patients before was 
reduced to 28% after BT injection (p = 0.0001). Soiling 
existed in 62% of patients before and was reduced to 8% 
after BT injection (p = 0.0001). Defecation intervals was  
9.1 days, and after BTX-A injection was reduced to 2.6 days  
(p = 0.0001). 
Nr 
Zhang et al., 
2014 [158] 
31 Xeomin—100 U 
After treatment, the pressure of the anal canal during rest 
and defecation was significantly reduced from (93 ± 16.5) 
mmHg and (105 ± 28.3) mm Hg to (63 ± 8.6.3) mm Hg and 
(42 ± 8.9) mm Hg, respectively. BT injection combined 
with pelvic floor biofeedback training achieved success in 
24 patients with 23 maintaining persistent satisfaction 
during a mean period of 8.4 months. 
8 fecal 
incontinence 
AR: Anterior rectocele; BFB: Biofeedback training; BT: Botulinum toxin; M: myectomy; Nr: Non reported; PD: Parkinson’s disease; 
PDPR: Partial division of puborectalis; SS score: Symptom severity score. 
An initial trial evaluating seven patients with constipation and anismus received BT of unknown dose 
into the EAS [141]. Symptom scores improved significantly correlating with a reduction in the maximum 
voluntary and anal canal squeeze pressure and a significant increase in the anorectal angle on straining 
with subsequent fecal incontinence in two patients. In another study, with a sample size of 4 patients 
with anismus, the dose of BT ranged from 6 to 15 units injected into the EAS or puborectalis muscle 
under electromyography guidance [144]. All four patients, who had numerous failed biofeedback 
sessions, responded to BT with two patients having sustained responses for up to one year. A larger 
study evaluating 15 patients at a dose of 25 BT units injected into the EAS showed improvement in  
13 patients (87%) for a mean of 4.8 months [143]. It is unclear whether BT should be injected into the 
EAS or the puborectalis muscle. Another study evaluated twenty-five patients who received 10 BT units 
on each side of the puborectalis muscle or 20 units in the posterior aspect of the muscle. Manometric 
relaxation was achieved after the first injection in 18 patients (75%), which endured throughout a  
six-month follow-up. Seven of 16 patients who failed the first injection had an additional one. Symptom 
improvement of 29.2% in straining index was recorded during follow-up with an overall satisfaction rate 
of 58.3%. Similar results have been noted in patients with Parkinson’s disease [149,159]. 
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Rectoceles are commonly associated with outlet obstruction, such as pelvic floor dyssenergia. 
Therefore, decreasing anal sphincter tone during strain may decrease the size of the rectocele and 
improve symptoms of constipation. In a study of fourteen patients with anterior rectocele, each patient 
received 30 BT units at three sites, two on either side of the puborectalis muscle and the third in the 
anterior portion of the external anal sphincter, under ultrasonographic guidance [145]. At two months, 
nine of fourteen patients had symptomatic improvement with a decrease in rectocele depth and area and 
decrease tone during straining. At one year, no patient experienced incomplete or required digitally 
assisted rectal voiding. 
BT use in the treatment of pelvic floor dyssenergia is still in its infancy with only small trials 
supporting its use. Many questions still remain such as the dose of BT, location of injection, use of 
ultrasound or electromyography, number of treatments, and combination with biofeedback. These 
questions need further study using placebo-controlled trials and larger sample sizes. 
6.2. Chronic Idiopathic anal Pain 
Chronic idiopathic anal pain is part of a rather ill-defined group of disorders termed chronic idiopathic 
perineal pain, which also includes proctalgia fugax and coccygodynia [160]. No objective abnormalities 
are found on clinical examination. The pathogenesis of the syndrome are unknown. There is no 
satisfactory treatment (anal stretch or surgery) for chronic anal pain. Eighteen patients who met the 
criteria for chronic idiopathic anal pain were studied. Treatment consisted of analgesics only in four 
patients, 0.2% nitroglycerin ointment in four, and ultrasound BT injection into the intersphincteric space 
in nine. Four patients were managed satisfactorily on analgesic treatment under the guidance of the 
hospital's pain clinic. Nitroglycerin ointment resulted in temporary pain relief in one of four patients. BT 
injection resulted in a permanent improvement in four patients, a temporary improvement in one patient, 
and no effect in four patients. Two patients had a colostomy, resulting in complete pain relief [160].  
As in other syndromes based on muscular dystonia, some patients may benefit from BT injection. 
6.3. Anal Fissure 
Anal fissures are tears in the anoderm that start at the anal verge and can extend to the dentate  
line [161–163]. They can manifest into painful defecation and rectal bleeding. These fissures, which 
most commonly arise in the mid-posterior position of the anus, are thought to occur secondary to 
ischemia as a result of increased anal sphincter pressures and decreased blood flow [164,165]. Once 
chronic fissures develop, treatment options are aimed at interrupting this cycle by reducing sphincter 
tone using topical nitroglycerin, BT injection, oral nifedipine, or LIS performed surgically [165]. There 
are many reports on the efficacy of BT for this condition (Table 4). 
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Table 4. Comparison of published results on the treatment of patients with chronic anal fissure. 
Author 
Cases  
(n) 
Units/injection’s 
Site 
Healing rate (%) Reinjection 
(%)/Dose 
Complete Healing 
Rate (%) 
Temporary 
Incontinence (%) 
Recurrence 
(%) 1 m 2 m 
Gui et al.,  
1994 [166] 
10 15 B/IAS 60 70 40/20 B 90 10 10 
Jost et al.,  
1994 [167] 
12 5 B/EAS Nr 83.3 - 83.3 0 8.3 
Jost et al.,  
1995 [168] 
54 5 B/EAS Nr 78 - 78 6 6 
Jost 1997 [169] 100 2.5–5 B/EAS Nr 82 - 82 7 8 
Maria et al.,  
1998 [6] 
15 20 B/IAS 53.3 73.3 
26.6/25 B 100 4 6.7 
15 Saline 13.3 13.3 
Maria et al.,  
1998 [170] 
23 15 B/IAS 21.7 43.5 8.7/20 B 100 
0 0 
34 20 B/IAS 50 67.6 20.6/25 B 100 
Minguez et al., 
1999 [171] 
23 10 B/IAS 48 
Nr 
52 83 
0 37–52 27 15 B/IAS 74 30 78 
19 21 B/IAS 100 37 90 
Jost and 
Schrank, 1999 
[172] 
25 20 D/EAS 
Nr 
76 
- 
76 4 4 
25 40 D/EAS 80 80 12 8 
Brisinda et al., 
1999 [173] 
25 20 B/IAS 88 96 
- 
96 
0 0 
25 0.2% GTN 40 60 60 
Fernandez et al. 
1999 [174] 
76 40 B/IAS 56 67 45.2/40 B 67 3 0 
Maria et al.,  
2000 [175] 
25 20 B/IAS PI 48 60 24/25 B 80 
0 0 
25 20 B/IAS AI 88 88 12/25 B 100 
Lysy et al.,  
2001 [176] 
15 20 B + ID/IAS 66 73 
- 
73 
0 0 
15 20 B/IAS 20 60 60 
Madalinski et al., 
2001 [177] 
14 25-50 B/EAS Nr 54 - 54 0 8 
Brisinda et al., 
2002 [178] 
75 20 B/IAS 73 89 10.7/30 B 100 0 0 
75 30 B/IAS 87 96 4/50 B 100 3 4 
Mentes et al., 
2003 [179] 
61 
20–30 B/IAS LIS 
62.3 73.8 
- 
86.9 0 11.4 
50 82 98 98 16 0 
Siproudhis et al., 
2003 [180] 
22 100 D/IAS 50 32 
Nr NR NR NR 
22 Saline 45 32 
Brisinda et al., 
2004 [181] 
50 50 B/IAS 82 92 - 92 22 
0 
50 150 D/IAS 84 94 6/150 D 94 16 
Giral et al.,  
2004 [182] 
10 20 B/IAS 
Nr 
70 
- 
70 
0 0 
11 LIS 82 82 
Simms et al., 
2004 [183] 
47 30 B/IAS Nr Nr 17/Nr 78.7 0 27 
Lindsey et al., 
2004 [184] 
30 25 B/IAS + FIS Nr Nr - 93 7 0 
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Table 4. Cont. 
Author 
Cases 
(n) 
Units/injection’s 
Site 
Healing rate (%) Reinjection 
(%)/Dose 
Complete Healing 
Rate (%) 
Temporary 
Incontinence (%) 
Recurrence 
(%) 1 m 2 m 
Arroyo et al., 
2005 [185] 
40 25 B/IAS Nr 85 
- 
45 5 55 
40 LIS  97.5 92.5 7.5 7.5 
Arroyo et al., 
2005 [186] 
100 25 B/IAS - 88 - 47 6 53 
De Nardi et al., 
2006 [187] 
15 20 B/IAS 33.3 53.3 
- 
33.3 0 33 
15 0.2% GTN 13.3 66.7 40  33 
Brisinda et al., 
2007 [188] 
50 30B/90D/IAS 82 92 
- 
92 0 0 
50 0.2% GTN 58 70 46 0 34 
Scholz et al., 
2007 [189] 
40 10 B/IAS + FIS 95  Nr 5/Nr 79 2.5 10 
Witte and Klaase, 
2007 [190] 
100 40–60 D/IAS Nr Nr 22/40–100 D 66 1 14 
Festen et al., 
2009 [191] 
37 20B/IAS + Poin 
Nr 
18.9 
21.6/20 B 
37.8 
17.8 
13.5 
36 1%ISDN + Pinj 44.4 58.3 25 
Nasr et al.,  
2010 [192] 
40 20 B/IAS 55 62.5 
- 
62.5 0 40 
40 LIS 80 90 90 10 12.5 
Samim et al., 
2012 [193] 
60 20 B/IAS 25 43 - 32 
5.5 
11.7 
74 2% Dz 14 43  26 17.6 
Valizadeh et al., 
2012 [194] 
25 50 B/IAS 28 44 
Nr 
48 12 50 
25 LIS 40  88 92 48 8 
Berkel et al., 
2014 [195] 
27 60 D/IAS 
Nr 
66.6 3.7/Nr 66.6 18.5 28 
33 1% ID 33.3  33.3 12 50 
Halahakoon et al., 
2014 [196] 
30 40 B/IAS + AF 86.7  Nr - 60 3.3 NR 
Farouk,  
2014 [197] 
141 100 B/IAS + FIS Nr Nr 14/Nr 76 8 18 
Gandomkar  
et al., 2015 
[198] 
49 
150D/IAS + 
2%Dz 
46.9 67.3 
- 
65.3 2 10.2 
50 LIS 74 92 94 7 0 
AI: Injection in anterior midline; AF: Advancement flap; B: Botox (trade name of the type A preparation manufactured by Allergan, CA, 
USA); D: Dysport (trade name of the type A preparation manufactured by IPSEN, Maidenhead, UK); Dz: Diltiazem; EAS: External anal 
sphincter; FIS: Fissurectomy; GTN: Glyceryl trinitrate; IAS: Internal anal sphincter; ID: Isosorbide dinitrate; LIS: Lateral internal 
sphincterotomy; NB: Neuroblock (trade name of the type B preparation manufactured by Elan Pharma International Ltd., Ireland); Nr: Not 
reported; PI: injection in posterior midline; Pinj: Placebo injection; Poin: Placebo ointment. 
These studies include several controlled trials comparing the toxin to either placebo or other 
modalities [6,170,173]. Clinical benefit is seen in the vast majority of patients, typically accompanied 
by reduction in resting anal sphincter pressure [175,178]. 
The exact site and dose of injection remains somewhat unsettled. Most of the trials to this point have 
evaluated BT administration at the point of the fissure, primarily, the posterior midline area of the anal 
verge. However, there is evidence that IAS fibrosis exists at the base of the fissure and is more prominent 
in this zone than other sites in the smooth muscle. This fibrosis may decrease the effects of BT on 
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sphincter relaxation, thus delaying fissure healing. A study to evaluate this theory was conducted on  
50 patients with posterior anal fissures who were either given 20 BT units lateral to the posterior fissure 
or 20 BT units on each side of the anterior midline [175]. After two months, a healing scar was observed 
in 15 patients (60%) of the posterior midline group and in 22 patients (88%) of the anterior midline 
group (p = 0.025). Resting anal pressure was significantly different from the baseline values at 1 and 2 
months in both groups, but the values were significantly lower in patients of the anterior midline group. 
Another study evaluated 150 patients with posterior anal fissures were treated with BT injected in the 
IAS on each side of the anterior midline. Patients were randomized to receive either 20 BT units and,  
if the fissure persisted, were retreated with 30 units, or 30 units and retreated with 50 units, if the fissure 
persisted [178]. One month after the injection, examinations revealed complete healing in 55 patients 
(73%) in the group receiving the lower dose and 65 patients (87%) in the group receiving the higher 
dose (p = 0.04). Five patients from the second group reported a mild incontinence of flatus that lasted  
2 weeks after the treatment and disappeared spontaneously. The values of the resting anal pressure  
(p = 0.3) and the maximum voluntary pressure (p = 0.2) did not differ between the two groups. However, 
after two months, healing rates were similar between the two groups (89% and 96%). The authors concluded 
that the higher dose was more effective, but the improved effectiveness was not seen at two months [178]. 
The gold standard for treatment for anal fissures is surgery, primarily LIS. However, surgical 
intervention is associated with a low complication rate resulting in fecal incontinence, hematoma, and 
wound infection. A study compared BT injection (20 to 30 units) and LIS [179]. Overall healing rates 
were similar in both groups at six months with 10 of 61 patients requiring a second BT injection at two 
months. However, the response rate was higher at 1 and 2 months in the sphincterotomy group;  
82% (41/50) at day 28 and 98% (49/50) at the second month (p = 0.023 and p < 0.0001, respectively, 
compared with the BT group). The response to BT was not as durable as surgery at 12 months falling to 
a success rate 75.4% (46/61) with seven recurrences in the BT group, whereas it remained stable in the 
LIS group (94%, p = 0.008). Sphincterotomy was associated with a significantly higher complication 
rate, eight cases of anal incontinence versus none in the BT group (p < 0.001) [179]. Thus, it appears 
that surgery is still the more durable treatment option but associated with more complications. These 
results have been supported in a more recent study. Some investigators have recommended surgery in 
younger patients and those with high resting anal pressures, as this is a risk factor for recurrence. Older 
patients may benefit from BT injection as they may be at higher risk of fecal incontinence. 
A recent meta-analysis showed that even though LIS is associated with a better healing rate and 
recurrence rate, BT treatment is superior to LIS in overall complication rates and incontinence  
rates [199]. Thus, some advantages BT offers to patients with anal fissure include a good tolerance of 
the procedure, an outpatient setting, and a low risk of incontinence. The results of the meta-analysis are 
in line with previous research [200]. Furthermore, in a recent study BT injection was used not only as a 
therapeutic tool but also as a diagnostic test to identify patients who would not be suitable for further 
surgical LIS if they developed temporary incontinence after BT injection [201]. Combination therapy 
such as nitroglycerine and BT has also been evaluated; it appears that this only results in a modest 
increase in the rate of healing [202,203]. 
BT injection is efficacious in the treatment of chronic anal fissures. With greater than 60% response 
rates noted at two months with further response to re-treatment, BT can be considered a viable treatment 
option when more conservative treatment fails. In elderly patients, in who rates of fecal incontinence 
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after surgery may be increased, BT can be considered first-line treatment. Surgery is still the most 
durable treatment option, but the risks of fecal incontinence must be weighed carefully against the 
benefits of the procedure. 
Thus, according to many authors we recommend a safety first approach and treat all patients medically 
in the first instance. We believe that specific indications for surgical intervention in patients with anal 
fissure include persistence/recurrence, noncompliance or intolerance to the medical treatment. Patients 
at higher incontinence risk can be evaluated by anorectal manometric and endoanal sonography test, or, 
at best, the patient should be offered a sphincter-sparing procedure. The need for further investigations 
imposes a cost increase. Furthermore, it is difficult to calculate the increased cost in the event of 
complications. Some of these patients may wish to avoid LIS and persist with an alternative medical therapy. 
Recently, Mishra et al. concluded that both treatments (NO donors and BT) may be considered as 
first-line treatment even if less effective than surgery [204]. However, this view has been challenged by 
other observations based on smaller series, providing inferior evidence of efficacy. The results of some 
studies are so disappointing that it led Nelson and coworkers to conclude a Cochrane review stating that 
“medical therapy for chronic anal fissure... may be applied with a chance of cure that is only marginally 
better than placebo.” [205]. We think that such conclusion is too pessimistic, and welcome further  
multi-center trials with appropriate methodology (intention-to-treat based selection of patients, doses, 
and injection technique) and adequate follow-up, to ascertain the safety and efficacy of the therapy. 
Moreover, the addition of multiple treatment modalities prolonged time to healing from initial 
evaluation, but allowed up to 75% of patients to avoid the need for permanent sphincter division while 
maintaining the highest rate of healing. 
We believe that the introduction of conservative therapies, and especially of BT, in the treatment of 
these patients represents an innovation equal to the introduction of laparoscopy. The introduction of 
these therapies has made the treatment of anal fissure easier, in the outpatient setting, at a lower cost and 
without permanent complications. On the other hands, laparoscopy has led to an increase in the cost of 
a single surgical procedure, often with a higher incidence of complications than open surgery. 
With regard to anal fissure, any conservative treatment used has lower costs than surgery [206]. 
Considering the three hypothetical scenarios reported in a recent paper, we found that the BT approach 
is more cost-effective than the ointment approach. In addition to cost reduction (on average 62% lower 
than the association NO donors plus surgery and on average 50% lower than the association CCA plus 
surgery), BT reduces the number of patients who need further surgery. Moreover, the preparation of 
incobotulinumtoxin A has a lower price than preparations onabotulinumtoxin A and abobotulinumtoxin A. 
This figure, given the similar clinical efficacy of the three formulations, would lead us to prefer the 
incobotulinumtoxin A [206]. It must be stressed, however, that the prices of the three formulations are 
not very dissimilar. 
We believe that BT is a safe treatment for anal fissure; it should be considered the first-line therapy 
in patients with chronic anal fissure. 
6.4. Other Anorectal Conditions 
BT into the IAS has been applied both diagnostically and therapeutically after pull-though surgery 
for Hirschsprung’s disease. Minkes and Langer prospectively evaluated 18 such children who underwent 
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BT injection (total dose 15–60 units) into 4 quadrants of the sphincter [207]. The authors have been 
showed improvement in 12 patients; improvement was sustained beyond 6 months in 5 of these patients. 
A total of 33 children with surgically treated Hirschsprung’s disease treated with intrasphincteric BT 
injection for obstructive symptoms were analyzed in a recent study [208]. The median time of follow up 
was 7.3 years. A median of two injections were given. Initial improvement was achieved in 76%, with 
a median duration of 4.1 months. Proportion of children hospitalized for enterocolitis decreased after 
treatment from 19 to 7. A good long-term response was found in 49%. Basson and coworkers have been 
studied 43 patients with idiopathic constipation, Hirschsprung’s disease, anorectal malformation and 
GIT dysmotility [209]. A total dose of 200 BT units has been injected. Successful outcomes occurred in 72% 
patients after the first BT treatment, and 25% required further surgical management of their symptoms. 
Pain after hemorrhoidectomy appears to be multifactorial; it seems be conceivable that IAS spasm is 
believed to play an important role [210]. The BT role in reducing pain after hemorrhoidectomy has been 
assessed in a double-blind study [211]. BT-treated patients have significantly less pain toward the end 
of the first week after surgery. 
7. Conclusions 
BT use for treatment of spastic GIT disorders has gained widespread acceptance over the last  
15 years, especially in the treatment of chronic anal fissures and achalasia. Its administration is generally 
safe and relatively non-invasive compared to many of the alternatives. However, its short-term duration 
of action in disorders that affect patients long-term is its most significant negative. Repeated 
administrations with are generally necessary, with noted loss of efficacy. 
The use of BT in many GIT disorders, although exciting, has not reached a level supported by clinical 
evidence. Further trials are needed with corresponding research to elucidate the pathophysiolgy of the 
spastic GIT disorders. 
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